Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Alerts
Advertising
Job board
Subscribe
Contact
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Next-Generation Sequencing in Medicine (Upcoming)
New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
Immunometabolism (Jan 2022)
Circadian Rhythm (Oct 2021)
Gut-Brain Axis (Jul 2021)
Tumor Microenvironment (Mar 2021)
100th Anniversary of Insulin's Discovery (Jan 2021)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Concise Communication
Editorials
Viewpoint
Top read articles
Clinical Medicine
JCI This Month
Current issue
Past issues
Polyglutamation of methotrexate. Is methotrexate a prodrug?
B A Chabner, … , J C Drake, J Jolivet
B A Chabner, … , J C Drake, J Jolivet
Published September 1, 1985
Citation Information:
J Clin Invest.
1985;
76(3)
:907-912.
https://doi.org/10.1172/JCI112088
.
View:
Text
|
PDF
Research Article
Polyglutamation of methotrexate. Is methotrexate a prodrug?
Text
PDF
Abstract
Authors
B A Chabner, C J Allegra, G A Curt, N J Clendeninn, J Baram, S Koizumi, J C Drake, J Jolivet
×
Other pages:
907
908
909
910
911
912
Other pages:
907
908
909
910
911
912